Where does Sarepta Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	——	——	——	——	-$248.39M-764%
Depreciation and amortization	$45.14M+15.9%	$44.52M+18.0%	$49.72M+28.7%	$41.08M+3.3%	$38.96M-6.9%
Stock-based compensation	$111.37M-39.8%	$123.4M-33.0%	$143.06M-20.7%	$171.58M-7.3%	$185.04M+1.7%
Change in accounts receivable	-$267.05M-195%	-$206.25M-202%	-$38.79M-134%	$167.3M+35.8%	$280.57M+81.0%
Change in inventories	$211.97M-58.6%	$319.57M-19.1%	$481.23M+46.9%	$468.75M+65.2%	$512.02M+146%
Change in accounts payable	——	——	——	——	——
Change in accrued liabilities	——	——	——	——	——
Change in other assets	——	——	——	——	——
Other working capital changes	-$5.33M—	-$7.06M—	——	——	——
Change in deferred revenue	-$117.47M—	$72.05M—	——	——	——
Net gains (losses) on investments	——	——	——	-$55.09M—	-$91.66M—
Net cash from operating activities	——	——	——	——	——
Capital expenditures	$60.4M-59.2%	$101.97M-25.5%	$136.46M+15.7%	$150.79M+36.7%	$148.16M+49.6%
Purchases of investments	——	——	——	——	$927.8M-49.4%
Proceeds from maturities/sales of investments	$172.23M+139%	$174.1M—	$174.1M+113%	-$629.78M-403%	-$436.93M-1,614%
Purchases of intangible assets	$6.64M—	$7.88M—	——	——	——
Net cash from investing activities	——	——	——	——	——
Proceeds from issuance of debt	——	——	——	——	——
Repayments of debt	——	——	——	——	——
Proceeds from issuance of common stock	$4.56M+171%	$20M—	$20M+141%	-$44.88M-259%	-$6.46M-9.5%
Net cash from financing activities	-$180.57M-257%	-$168.34M-235%	-$80.15M-203%	$51.4M-35.3%	$115.14M+154%
Net increase (decrease) in cash	——	——	——	——	-$186.42M+58.4%
Interest paid	$31.14M+96.4%	$14.91M-5.9%	$14.65M-8.2%	$15.06M-6.4%	$15.86M-1.4%
Income taxes paid	$38.53M+71.1%	$37.63M+66.6%	$32.22M+88.1%	$34.69M+103%	$22.51M+45.7%
Accretion Of Investment Discount Net	-$3.91M+86.9%	-$5.29M+86.9%	-$11.71M+75.0%	-$21.2M+56.6%	-$29.79M+40.3%
Gain (Loss) on Investments	——	——	——	——	——
Accrued expenses and other liabilities	——	——	——	——	——
Deferred revenue	-$117.47M—	$72.05M—	——	——	——
Increase Decrease In Manufacturing Related Deposits And Prepaids	——	——	——	——	——
Increase (Decrease) in Other Operating Assets	——	——	——	——	——
Non Cash Inventory Write Downs For Excess And Obsolescence	——	$165.26M—	$123.94M—	$82.63M—	$41.31M—
Noncash Interest Expense	——	——	——	——	——
Other Noncash Income (Expense)	-$5.33M—	-$7.06M—	——	——	——
Reduction In The Carrying Amounts Of The Right Of Use Assets	$13.13M-18.7%	$13.95M-13.7%	$15.2M-5.8%	$16.16M+3.3%	$16.15M+6.0%
Acquisition Of Strategic Investments	——	——	——	-$245.82M-12,191%	-$241.39M-7,946%
Payments to Acquire Intangible Assets	$6.64M—	$7.88M—	——	——	——
Proceeds From Sale And Maturity Of Available For Sale Securities	$294M-81.2%	$295.87M-85.2%	$1.16B-25.8%	$1.37B-21.3%	$1.57B-17.5%
Payment On Maturity Of Notes	——	$0-100%	$17K-66.7%	$34K0.0%	$51K+200%
Payments Related To Obtaining Revolving Credit Facility	$960K-70.1%	$4.17M—	$4.12M—	$3.51M—	$3.21M—
Settlement Of Capped Call Share Options For2024Notes	——	$0-100%	$11.34M-79.1%	$22.67M-64.0%	$34.01M-52.6%
Contingent Consideration Liabilities Derecognized	——	$47.4M—	$35.55M—	$23.7M—	$11.85M—
Incremental Option Value Associated With The December2025Exchange	——	$21.08M—	$15.81M—	$10.54M—	$5.27M—
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1	——	——	——	——	$49.04M—
Remeasurement Of Embedded Lease Liabilities	——	$12.27M—	$9.2M—	$6.14M—	$3.07M—
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	$40.32M-49.7%
Income Taxes Paid, Net	$38.53M+71.1%	$37.63M+66.6%	$32.22M+88.1%	$34.69M+103%	$22.51M+45.7%
Free cash flow	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Sarepta Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.